Best-of
GLP-1 Without Needles (2026): Pills, Lozenges and Drops Compared
Two FDA-approved oral GLP-1s now exist at $149 to start, both with published trial data. Compounded oral, sublingual and lozenge products cost $165 to $369 with no trial
Two FDA-approved oral GLP-1s now exist at $149 to start, both with published trial data. Compounded oral, sublingual and lozenge products cost $165 to $369 with no trial evidence and unpublished bioavailability — every one of them above the approved price.
Three categories, not two
Approved orals. Orforglipron (Foundayo), approved 1 April 2026, and oral semaglutide 25 mg (the Wegovy pill), approved 22 December 2025. Each went through its own trial programme for the oral formulation.
Compounded orals, sublinguals and lozenges. No trial has tested any of them. Bioavailability for these specific preparations is unpublished.
Injectables. Still where every efficacy figure in this field comes from.
Why oral delivery is genuinely hard
An injected peptide bypasses digestion. Taken by mouth it faces stomach acid, enzymes and poor absorption. Oral semaglutide solves this with an absorption enhancer — which is why it must be taken in the morning on an empty stomach, with no more than four ounces of water, waiting 30 minutes before eating or drinking.
Orforglipron sidesteps the problem entirely by being a small molecule rather than a peptide, which is why it has no food or water restrictions.
A compounded orally disintegrating tablet inherits neither solution.
What the market charges
Approved: $149 to start for either. Compounded: $165 to $369 across ODT, sublingual and oral drops. Every compounded option in our dataset costs more than an approved oral at its starting dose.
That is the clearest case in this category of a compounded product costing more than the approved alternative while having no evidence of its own.
Honest guidance
If needles are the barrier, the approved orals are the route with data behind them — and with a savings card or Medicare eligibility they can be $25 to $50.
If price is the barrier, the cheapest options in this market are compounded injectables, from around $147.
The compounded oral category is currently hard to justify on either axis, and we say that even though several providers we cover sell it.
Show this figure as a table
| Item | Mean reduction | Evidence |
|---|---|---|
| Tirzepatide 15 mg (SURMOUNT-1) | 21% | Verified |
| Oral semaglutide 25 mg, adherent (OASIS 4) | 17% | Verified |
| Injectable semaglutide 2.4 mg (SURMOUNT-5) | 14% | Verified |
| Oral semaglutide 25 mg, treatment-policy (OASIS 4) | 14% | Verified |
| Orforglipron 17.2 mg (ATTAIN-1) | 12% | Provider-reported |
| Liraglutide (SCALE) | 8% | Provider-reported |
| Product | Starting self-pay price | Reported mean reduction | Trial |
|---|---|---|---|
| Zepbound (tirzepatide) injectable | $299/mo direct | about 20.9% at 15 mg | SURMOUNT-1, 72 weeks |
| Wegovy pill (oral semaglutide 25 mg) | $149/mo starting dose | 13.6–16.6% depending on estimand | OASIS 4, 64 weeks |
| Wegovy injectable (semaglutide 2.4 mg) | $349/mo maintenance | about 13.7% | SURMOUNT-5, 72 weeks |
| Foundayo (orforglipron) | $149/mo starting dose | about 11–12.4% at 17.2 mg | ATTAIN-1, 72 weeks |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
| Cost component | Inside the advertised figure? | Charged anyway? |
|---|---|---|
| Medication | yes | yes |
| Membership or program fee | no | not verified |
| Shipping | no | not verified |
| Higher-dose surcharge | no | not verified |
| Initial consultation | no | not verified |
| Required laboratory work | no | not verified |
| Cancellation or restocking terms | no | not verified |
54 captured records across 23 providers, ranging $110 to $2048 a month all-in. 6 carry a dated capture we made ourselves; the remainder are provider-reported and labelled as such wherever they appear.
Related on this site
- Provider ranking methodologyCore & Trust
- GLP-1 total cost calculatorTools
- Download the pricing recordsData
- Best Tirzepatide Providers Online in 2026Pillar / Money
- BMI CalculatorTools
- Authors and AnalystsCore & Trust
- Annual GLP-1 Cost CalculatorTools
- Affiliate and Commercial DisclosureCore & Trust
- Advertising and Sponsored Content PolicyCore & Trust
- bmiMD Tirzepatide ReviewProviders
GLP-1 Tirzepatide Review. “GLP-1 Without Needles (2026): Pills, Lozenges and Drops Compared.” S.J Partners LLC, 2026-07-24. https://glp1tirzepatidereview.com/glp1-without-needles/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.